EntryPoint Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

EntryPoint Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,487	Closed	-$127K	–	740
2025 Q4	$127K	Sell	10,487 -6,679	-39%	-$90.7K	0.05%	598
2025 Q3	$233K	Buy	+17,166	New	+$162K	0.09%	488
2025 Q2	–	Sell	-10,587	Closed	-$37.5K	–	604
2025 Q1	$37.5K	Sell	10,587 -3,322	-24%	-$11.8K	0.02%	645
2024 Q4	$52.6K	Buy	+13,909	New	+$65.5K	0.02%	689

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

EntryPoint Capital's AMLX Position: Q1 2026 in Review

EntryPoint Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 10,487 shares — an estimated $127K sold.

EntryPoint Capital first reported a position in AMLX in Q4 2024 and held it in 4 quarters. The position peaked at $233K in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

EntryPoint Capital reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
EntryPoint Capital sold 10,487 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $127K.
EntryPoint Capital first reported a position in Amylyx Pharmaceuticals in Q4 2024 and held it in 4 quarters.
EntryPoint Capital's Amylyx Pharmaceuticals position peaked at $233K in Q3 2025.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.